Your email has been successfully added to our mailing list.

×
-0.0197995600097774 -0.0197995600097774 -0.0208995355658762 -0.0241994622341725 -0.0227328281593741 -0.0256660963089708 -0.0272549498900023 -0.0319237350281104
Stock impact report

BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test [Reuters]

ROCHE HOLDING LTD S/ADR (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
Company Research Source: Reuters
BRIEF-Roche Receives FDA Approval For Cervical Cancer Prevention Test March 11 (Reuters) - Roche Holding AG: * ROCHE RECEIVES FDA APPROVAL FOR CINTEC PLUS CYTOLOGY TEST TO AID CLINICIANS IN IMPROVING CERVICAL CANCER PREVENTION * NEXT-GENERATION CYTOLOGY TEST PROVIDES ADDITIONAL INFORMATION FOR HPV-POSITIVE WOMEN WHO MAY HAVE CERVICAL PRE-CANCER Source text for Eikon: Further company coverage: (Berlin Speed Desk) Show less Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
RHHBY alerts

from News Quantified
Opt-in for
RHHBY alerts

from News Quantified